Title:
HETEROARYL COMPOUNDS AS INHIBITORS OF USP1
Document Type and Number:
WIPO Patent Application WO/2024/022266
Kind Code:
A1
Abstract:
The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provided are the compounds of any of formula (I) to (XXII), pharmaceutically acceptable salts or pharmaceutical compositions. Definition of each group in the formula can be found in the specification for details.
Inventors:
CHAI YONGSHUAI (CN)
WANG ZHAOYIN (CA)
LI LINTONG (US)
LI NANXIN (US)
WANG ZHAOYIN (CA)
LI LINTONG (US)
LI NANXIN (US)
Application Number:
PCT/CN2023/108789
Publication Date:
February 01, 2024
Filing Date:
July 24, 2023
Export Citation:
Assignee:
GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD (CN)
International Classes:
A61P35/00; C07D473/00; C07D471/04; C07D487/04; C07D498/04
Domestic Patent References:
| WO2021247606A1 | 2021-12-09 | |||
| WO2022174184A1 | 2022-08-18 | |||
| WO2022199652A1 | 2022-09-29 | |||
| WO2022214053A1 | 2022-10-13 | |||
| WO2022216820A1 | 2022-10-13 | |||
| WO2022228399A1 | 2022-11-03 | |||
| WO2022233263A1 | 2022-11-10 | |||
| WO2023030295A1 | 2023-03-09 | |||
| WO2023066299A1 | 2023-04-27 | |||
| WO2023083285A1 | 2023-05-19 | |||
| WO2023083297A1 | 2023-05-19 |
Foreign References:
| CN108473495A | 2018-08-31 | |||
| CN113164485A | 2021-07-23 |
Attorney, Agent or Firm:
SHANGHAI ZHI XIN PATENT AGENT LTD. (CN)
Download PDF: